Pulmonx Maintains $90M-$92M Revenue Outlook for 2026 with ~76% Gross Margin Target
In Q2 2026, Pulmonx reported total worldwide revenue of $22.8 million, in line with expectations as the company continues to regain commercial traction. CEO Glendon French stated that progress is unfolding as anticipated. The firm reaffirmed its full-year revenue guidance for 2026 between $90 million and $92 million while targeting a gross margin of approximately 76%. This outlook reflects ongoing efforts to strengthen market position following earlier challenges. The update comes amid continued focus on commercial recovery, with the company emphasizing that current performance aligns with strategic goals. Investors are likely watching closely for signs of sustained growth as Pulmonx works toward its long-term financial targets.
Tickers: $LUNG
Topics: financial_results revenue